Home > Newsletters > FDAnews Drug Daily Bulletin > FDA OKs Pfizer’s Lyrica to Treat Neuropathic Pain Due to Spinal Cord Injury
FDAnews Drug Daily Bulletin
June 25, 2012 | Vol. 9 No. 124
FDA OKs Pfizer’s Lyrica to Treat Neuropathic Pain Due to Spinal Cord Injury
The FDA has approved an expanded indication for Pfizer’s Lyrica CV to treat neuropathic pain due to spinal cord injury, boosting the pharma giant’s fast-growing pain management portfolio. In green-lighting Pfizer’s sNDA for Lyrica (pregabalin), the agency has advanced a first-of-its-kind treatment in the U.S. for a pain condition that almost half of all spinal injury patients suffer from, the drugmaker said Thursday.
Drug Industry Daily
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.